

## 6 Anhang

### 6.1 Literaturverzeichnis

1. Starzl, T.E., et al., *Homotransplantation of the Liver in Humans*. Surg Gynecol Obstet, 1963. **117**: p. 659-76.
2. *National Institutes of Health Consensus Development Conference on Liver Transplantation. Sponsored by the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases and the National Institutes of Health Office of Medical Applications of Research*. Hepatology, 1984. **4 (1 Suppl)**: p. 1S-110S.
3. Devlin, J. and J. O'Grady, *Indications for referral and assessment in adult liver transplantation: a clinical guideline*. British Society of Gastroenterology. Gut, 1999. **45 Suppl 6**: p. VI1-VI22.
4. *Consensus statement on indications for liver transplantation: Paris, June 22-23, 1993*. Hepatology, 1994. **20 (1 Pt 2)**: p. 63S-68S.
5. ELTR, *Patient and graft survival following liver transplantation in Europe*. 2006.
6. UNOS, *National Data Reports*. 2005.
7. Neuhaus, P., et al., *Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience*. Transplantation, 1995. **59(1)**: p. 31-40.
8. *Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection*. European FK506 Multicentre Liver Study Group. Lancet, 1994. **344(8920)**: p. 423-8.
9. Rimm, E.B., et al., *Prospective study of alcohol consumption and risk of coronary disease in men*. Lancet, 1991. **338(8765)**: p. 464-8.
10. Sesso, H.D., *Alcohol and cardiovascular health: recent findings*. Am J Cardiovasc Drugs, 2001. **1(3)**: p. 167-72.
11. Greenfield, J.R., et al., *Beneficial postprandial effect of a small amount of alcohol on diabetes and cardiovascular risk factors: modification by insulin resistance*. J Clin Endocrinol Metab, 2005. **90(2)**: p. 661-72.
12. Barber, J.G. and B.R. Crisp, *The effects of alcohol abuse on children and the partner's capacity to initiate change*. Drug Alcohol Rev, 1994. **13(4)**: p. 409-16.
13. Smith, C.L., et al., *Children's coping strategies and coping efficacy: relations to parent socialization, child adjustment, and familial alcoholism*. Dev Psychopathol, 2006. **18(2)**: p. 445-69.
14. Rayner, M., *European Union policy and health*. Bmj, 1995. **311(7014)**: p. 1180-1.
15. Gil Lopez, E., et al., *[The European Alcohol Action Plan. The Alcohol, Drug and Tobacco Unit. Department of Lifestyles and Health, Regional Office for Europe. World Health Organization. Copenhagen, 1993]*. Rev Esp Salud Publica, 1995. **69(5)**: p. 361-83.
16. Corrao, G., et al., *Exploring the dose-response relationship between alcohol consumption and the risk of several alcohol-related conditions: a meta-analysis*. Addiction, 1999. **94(10)**: p. 1551-73.
17. Diehl, A.M., *Liver disease in alcohol abusers: clinical perspective*. Alcohol, 2002. **27(1)**: p. 7-11.

18. Purohit, V., D. Russo, and P.M. Coates, *Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium*. Alcohol, 2004. **34**(1): p. 3-8.
19. French, S.W., et al., *Pathology of alcoholic liver disease. VA Cooperative Study Group 119*. Semin Liver Dis, 1993. **13**(2): p. 154-69.
20. *Alcoholic liver disease: morphological manifestations. Review by an international group*. Lancet, 1981. **1**(8222): p. 707-11.
21. Lieber, C.S., *Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis*. Alcohol, 2004. **34**(1): p. 9-19.
22. Stremmel, W., et al., [*Therapy of alcoholic and non-alcoholic fatty liver*]. Internist (Berl), 2001. **42**(12): p. 1641-2, 1645-50.
23. Fletcher, L.M., K.R. Bridle, and D.H. Crawford, *Effect of alcohol on iron storage diseases of the liver*. Best Pract Res Clin Gastroenterol, 2003. **17**(4): p. 663-77.
24. Yersin, B., et al., *Screening for excessive alcohol drinking. Comparative value of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume*. Arch Intern Med, 1995. **155**(17): p. 1907-11.
25. Golka, K., et al., *Carbohydrate-deficient transferrin (CDT) as a biomarker in persons suspected of alcohol abuse*. Toxicol Lett, 2004. **151**(1): p. 235-41.
26. Conigrave, K.M., et al., *Traditional markers of excessive alcohol use*. Addiction, 2003. **98 Suppl 2**: p. 31-43.
27. Cohen, J.A. and M.M. Kaplan, *The SGOT/SGPT ratio--an indicator of alcoholic liver disease*. Dig Dis Sci, 1979. **24**(11): p. 835-8.
28. Nyblom, H., et al., *High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking*. Alcohol Alcohol, 2004. **39**(4): p. 336-9.
29. Sorbi, D., J. Boynton, and K.D. Lindor, *The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease*. Am J Gastroenterol, 1999. **94**(4): p. 1018-22.
30. ELTR, *Primäre Indikationen für Lebertransplantationen in Europa 1988-2003*. 2004.
31. White, I.R., D.R. Altmann, and K. Nanchahal, *Alcohol consumption and mortality: modelling risks for men and women at different ages*. Bmj, 2002. **325**(7357): p. 191.
32. Neuberger, J., et al., *Transplantation for alcoholic liver disease*. J Hepatol, 2002. **36**(1): p. 130-7.
33. Gavaler, J.S., *Sex-related differences in ethanol-induced liver disease: artifactual or real?* Alcohol Clin Exp Res, 1982. **6**(2): p. 186-96.
34. Morgan, M.Y., *The prognosis and outcome of alcoholic liver disease*. Alcohol Alcohol Suppl, 1994. **2**: p. 335-43.
35. Pares, A., et al., *Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage*. J Hepatol, 1986. **2**(1): p. 33-42.
36. Diehl, A.M., *Obesity and alcoholic liver disease*. Alcohol, 2004. **34**(1): p. 81-7.
37. Naveau, S., et al., *Excess weight risk factor for alcoholic liver disease*. Hepatology, 1997. **25**(1): p. 108-11.
38. Yang, S.Q., et al., *Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis*. Proc Natl Acad Sci U S A, 1997. **94**(6): p. 2557-62.
39. Hrubec, Z. and G.S. Omenn, *Evidence of genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism and its biological end points by zygosity among male veterans*. Alcohol Clin Exp Res, 1981. **5**(2): p. 207-15.
40. Prescott, C.A., et al., *Is risk for alcoholism mediated by individual differences in drinking motivations?* Alcohol Clin Exp Res, 2004. **28**(1): p. 29-39.

41. Prescott, C.A., et al., *The Washington University Twin Study of alcoholism*. Am J Med Genet B Neuropsychiatr Genet, 2005. **134**(1): p. 48-55.
42. Starzl, T.E., et al., *Orthotopic liver transplantation for alcoholic cirrhosis*. Jama, 1988. **260**(17): p. 2542-4.
43. Everson, G., et al., *Long-term follow-up of patients with alcoholic liver disease who underwent hepatic transplantation*. Liver Transpl Surg, 1997. **3**(3): p. 263-74.
44. Lucey, M.R., et al., *Selection for and outcome of liver transplantation in alcoholic liver disease*. Gastroenterology, 1992. **102**(5): p. 1736-41.
45. Wiesner, R.H., et al., *Liver transplantation for end-stage alcoholic liver disease: an assessment of outcomes*. Liver Transpl Surg, 1997. **3**(3): p. 231-9.
46. Hoofnagle, J.H., et al., *Liver transplantation for alcoholic liver disease: executive statement and recommendations. Summary of a National Institutes of Health workshop held December 6-7, 1996, Bethesda, Maryland*. Liver Transpl Surg, 1997. **3**(3): p. 347-50.
47. Tavill, A.S. and A.M. Qadri, *Alcohol and iron*. Semin Liver Dis, 2004. **24**(3): p. 317-25.
48. Rouault, T.A., *Hepatic iron overload in alcoholic liver disease: why does it occur and what is its role in pathogenesis?* Alcohol, 2003. **30**(2): p. 103-6.
49. Jain, A., et al., *Long-term survival after liver transplantation in 4,000 consecutive patients at a single center*. Ann Surg, 2000. **232**(4): p. 490-500.
50. Adam, R., et al., *Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study*. Lancet, 2000. **356**(9230): p. 621-7.
51. Sebagh, M., et al., *All liver recipients benefit from the protocol 10-year liver biopsies*. Hepatology, 2003. **37**(6): p. 1293-301.
52. Henley, K.S., et al., *Biochemical and histopathological correlation in liver transplant: the first 180 days*. Hepatology, 1992. **16**(3): p. 688-93.
53. Rifai, K., et al., *Donor age influences 10-year liver graft histology independently of hepatitis C virus infection*. J Hepatol, 2004. **41**(3): p. 446-53.
54. Staatz, C.E. and S.E. Tett, *Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation*. Clin Pharmacokinet, 2004. **43**(10): p. 623-53.
55. Levy, G.A., *Long-term immunosuppression and drug interactions*. Liver Transpl, 2001. **7**(11 Suppl 1): p. S53-9.
56. Fung, J., et al., *Immunosuppression in liver transplantation: beyond calcineurin inhibitors*. Liver Transpl, 2005. **11**(3): p. 267-80.
57. Barshes, N.R., et al., *Risk stratification of adult patients undergoing orthotopic liver transplantation for fulminant hepatic failure*. Transplantation, 2006. **81**(2): p. 195-201.
58. Ghobrial, R.M., et al., *Pretransplant model to predict posttransplant survival in liver transplant patients*. Ann Surg, 2002. **236**(3): p. 315-22; discussion 322-3.
59. Neuhaus, P.a.P., R., *Aktuelle Aspekte der Lebertransplantation*. 1 ed, ed. U.-M.V.A. 85. Vol. 1. 2003.
60. Neuhaus, P., et al., *Technique and results of biliary reconstruction using side-to-side choledochocholedochostomy in 300 orthotopic liver transplants*. Ann Surg, 1994. **219**(4): p. 426-34.
61. Platz, K.P., et al., *Management of acute steroid-resistant rejection after liver transplantation*. World J Surg, 1996. **20**(8): p. 1052-8; discussion 1058-9.
62. Ciesek, S., M.P. Manns, and C.P. Strassburg, [*Sequelae of organ transplantation.*]. Internist (Berl), 2006. **47**(3): p. 252-65.

63. Bell, H., et al., *Long-term prognosis of patients with alcoholic liver cirrhosis: a 15-year follow-up study of 100 Norwegian patients admitted to one unit*. Scand J Gastroenterol, 2004. **39**(9): p. 858-63.
64. Pessione, F., et al., *Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence*. Liver Int, 2003. **23**(1): p. 45-53.
65. Cho, J.Y., et al., *The clinical significance of early histological rejection with or without biochemical abnormality in adult living donor liver transplantation for hepatitis B virus related end stage liver disease*. Transpl Int, 2007. **20**(1): p. 37-44.
66. Schemmer, P., et al., *Extended donor criteria have no negative impact on early outcome after liver transplantation: a single-center multivariate analysis*. Transplant Proc, 2007. **39**(2): p. 529-34.
67. Quintieri, F., et al., *Liver transplantation in Italy: analysis of risk factors associated with graft outcome*. Prog Transplant, 2006. **16**(1): p. 57-64.
68. Hong, Z., et al., *Survival analysis of liver transplant patients in Canada 1997-2002*. Transplant Proc, 2006. **38**(9): p. 2951-6.
69. Ioannou, G.N., *Development and validation of a model predicting graft survival after liver transplantation*. Liver Transpl, 2006. **12**(11): p. 1594-606.
70. Kowdley, K.V., et al., *Survival after liver transplantation in patients with hepatic iron overload: the national hemochromatosis transplant registry*. Gastroenterology, 2005. **129**(2): p. 494-503.
71. Adam, R., et al., *Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry*. Liver Transpl, 2003. **9**(12): p. 1231-43.
72. Cohen, C. and M. Benjamin, *Alcoholics and liver transplantation. The Ethics and Social Impact Committee of the Transplant and Health Policy Center*. Jama, 1991. **265**(10): p. 1299-301.
73. Lucey, M.R. and T.P. Beresford, *Alcoholic liver disease: to transplant or not to transplant?* Alcohol Alcohol, 1992. **27**(2): p. 103-8.
74. Moss, A.H. and M. Siegler, *Should alcoholics compete equally for liver transplantation?* Jama, 1991. **265**(10): p. 1295-8.
75. Schenker, S., H.S. Perkins, and M.F. Sorrell, *Should patients with end-stage alcoholic liver disease have a new liver?* Hepatology, 1990. **11**(2): p. 314-9.
76. Krom, R.A., *Liver transplantation and alcohol: who should get transplants?* Hepatology, 1994. **20**(1 Pt 2): p. 28S-32S.
77. Lucey, M.R., et al., *Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases*. Transplantation, 1998. **66**(7): p. 956-62.
78. Pageaux, G.P., et al., *Alcoholic cirrhosis is a good indication for liver transplantation, even for cases of recidivism*. Gut, 1999. **45**(3): p. 421-6.
79. Tome, S., et al., *Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage alcoholic liver disease*. J Hepatol, 2002. **36**(6): p. 793-8.
80. McCurry, K.R., et al., *Resource utilization and outcome of liver transplantation for alcoholic cirrhosis. A case-control study*. Arch Surg, 1992. **127**(7): p. 772-6; discussion 776-7.
81. Knechtle, S.J., et al., *Liver transplantation for alcoholic liver disease*. Surgery, 1992. **112**(4): p. 694-701; discussion 701-3.
82. Poynard, T., et al., *Evaluation of efficacy of liver transplantation in alcoholic cirrhosis by a case-control study and simulated controls*. Lancet, 1994. **344**(8921): p. 502-7.

83. Chedid, A., et al., *Prognostic factors in alcoholic liver disease. VA Cooperative Study Group*. Am J Gastroenterol, 1991. **86**(2): p. 210-6.
84. Sebagh, M. and D. Samuel, *Place of the liver biopsy in liver transplantation*. J Hepatol, 2004. **41**(6): p. 897-901.
85. Maor-Kendler, Y., et al., *Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases*. Transplantation, 2000. **70**(2): p. 292-7.
86. Rodriguez-Luna, H. and D.D. Douglas, *Natural history of hepatitis C following liver transplantation*. Curr Opin Infect Dis, 2004. **17**(4): p. 363-71.
87. *NIH Consensus Statement on Management of Hepatitis C: 2002*. NIH Consens State Sci Statements, 2002. **19**(3): p. 1-46.
88. Babatin, M., L. Schindel, and K.W. Burak, *Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy*. Can J Gastroenterol, 2005. **19**(6): p. 359-65.

## **6.2 Tabellenverzeichnis**

**Tabelle 1:** Indikationen zur Lebertransplantation bei 1521 Patienten

**Tabelle 2:** Histologische Kriterien der Beurteilung

**Tabelle 3:** Histologische Ergebnisse der explantierten Organe

**Tabelle 4:** Histologische Ergebnisse der 1-Jahres-Biopsie

**Tabelle 5:** Histologische Ergebnisse der 3-Jahres-Biopsie

**Tabelle 6:** Histologische Ergebnisse der 5-Jahres-Biopsie

**Tabelle 7:** Histologische Ergebnisse der 7-Jahres-Biopsie

**Tabelle 8:** Histologische Ergebnisse der 10-Jahres-Biopsie

**Tabelle 9:** Histologische Ergebnisse der 13-Jahres-Biopsie

**Tabelle 10:** Unterschiede in der Fibroseentwicklung bei Alkoholabstinenz und Konsum

**Tabelle 11:** Unterschiedliche Entwicklung der Verfettung bei Alkoholabstinenz und Konsum

**Tabelle 12:** Biopsieergebnisse der HCC-Gruppe I

**Tabelle 13:** Biopsieergebnisse der HCC-Gruppe II

**Tabelle 14:** Histologische Unterschiede bei Patienten mit HCC vs. Patienten ohne HCC I

**Tabelle 15:** Histologische Unterschiede bei Patienten mit HCC vs. Patienten ohne HCC II

**Tabelle 16:** Einflussfaktoren auf das Überleben

**Tabelle 17:** Histologische Ergebnisse nach 5 Jahren ohne Alkohol

**Tabelle 18:** Histologische Ergebnisse nach 10 Jahren ohne Alkohol

**Tabelle 19:** Histologien nach 5 Jahren mit und ohne Rejektionen im Verlauf

**Tabelle 20:** Histologien nach 10 Jahren mit und ohne Rejektionen im Verlauf

**Tabelle 21:** Histologien nach 5 Jahren bei kalter Ischämiezeit  $<12$  und  $\geq 12$  Stunden

**Tabelle 22:** Histologien nach 10 Jahren bei kalter Ischämiezeit  $<12$  und  $\geq 12$  Stunden

**Tabelle 23:** Histologien nach 5 Jahren bei Spenderalter  $<50$  und  $\geq 50$  Jahre

**Tabelle 24:** Histologien nach 10 Jahren bei Spenderalter  $<50$  und  $\geq 50$  Jahre

### **6.3 Abbildungsverzeichnis**

- Abb. 1:** Primäre Indikationen für Lebertransplantationen in Europa 1988-2003 °
- Abb. 2:** Aufteilung der Indikation Leberzirrhose in Europa 1988-2003 °
- Abb. 3:** Steatosis hepatis, makrovesikulär\*
- Abb. 4:** Steatosis hepatis, makrovesikulär\*
- Abb. 5:** Alkoholische Steatohepatitis, Grad 2\*
- Abb. 6:** Leberzirrhose, kleinknotig\*
- Abb. 7:** Leberzirrhose, kleinknotig\*
- Abb. 8:** Geschlechterverteilung bei Erkrankungsrezidiv und Alkoholabstinenz nach LTx
- Abb. 9:** Kaplan-Meier-Überlebenskurven bei Alkoholabstinenz und Alkoholrezidiv
- Abb. 10:** Kaplan-Meier-Überlebenskurve bei Patienten mit HCC
- Abb. 11:** Kaplan-Meier-Überlebenskurven bei Patienten mit HCC vs. ohne HCC
- Abb. 12:** Kaplan-Meier-Überlebenskurven bei kalter Ischämiezeit < 12 und ≥12 Stunden
- Abb. 13:** Kaplan-Meier-Überlebenskurven mit und ohne Rejektionen im Verlauf
- Abb. 14:** Kaplan-Meier-Überlebenskurven bei Empfängeralter < 60 und ≥ 60 Jahre
- Abb. 15:** Kaplan-Meier-Überlebenskurven bei Empfängeralter < 50 und ≥ 50 Jahre
- Abb. 16:** Kaplan-Meier-Überlebenskurven der Empfänger im Geschlechtervergleich
- Abb. 17:** Kaplan-Meier-Überlebenskurven bei Spenderalter < 60 und ≥ 60 Jahre
- Abb. 18:** Kaplan-Meier-Überlebenskurven bei Spenderalter < 50 und ≥ 50 Jahre
- Abb. 19:** Kaplan-Meier-Überlebenskurven bei Geschlechtsunterschieden der Spender

\* mit freundlicher Genehmigung des Pathologische Instituts der Charité Berlin

° European Liver Transplant Registry, Stand Oktober 2004